Trial Profile

A Clinical Study Of Enadenotucirev Administered by Sub-Acute Fractionated Intravenous Injection: Dose Escalation in Metastatic Epithelial Solid Tumours and Randomised Controlled Trial in Metastatic Colorectal Cancer

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 06 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Enadenotucirev (Primary)
Indications Bladder cancer; Carcinoma; Colorectal cancer; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours; Urogenital cancer
Focus Adverse reactions; First in man; Therapeutic Use
Acronyms EVOLVE
Sponsors Akamis Bio; PsiOxus Therapeutics

05 Jan 2023 According to an Akamis Bio media release, PsiOxus Therapeutics has changed its name to Akamis Bio.
20 Mar 2018 Status changed from active, no longer recruiting to completed.
11 Oct 2016 Results assessing the pattern of enadenotucirev delivery within tumors in patients with colon, lung, bladder and renal carcinoma (n=17) presented at the 41st European Society for Medical Oncology Congress.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com